Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Enveric Biosciences Inc. - news published 259 - readings 4.281

BACK

Enveric Biosciences Inc.

Regulation FD Presentation (Form 8-K)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Enveric Biosciences Inc. published this content on February 26, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 26, 2025 at 13:34:25.506 .

26.02.2025

Enveric Biosciences Inc.

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Press Releases Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease By wpengine February 4, 2025 No Comments Licensee, Restoration Biologics, is uniquely positioned to advance care in treating joint disease CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology compan ...

04.02.2025

Enveric Biosciences Inc.

Enveric Biosciences Announces Pricing of $5 Million Public Offering (Form 8-K)

Enveric Biosciences Announces Pricing of $5 Million Public Offering CAMBRIDGE, Mass., January 30, 2025 - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today ann ...

03.02.2025

Enveric Biosciences Inc.

Enveric Biosciences Announces Closing of $5 Million Public Offering

Press Releases Enveric Biosciences Announces Closing of $5 Million Public Offering By wpengine February 3, 2025 No Comments CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depressi ...

03.02.2025

Enveric Biosciences Inc.

Supplemental Prospectus (Form 424B4)

Filed Pursuant to Rule 424(b)(4) Registration No. 333-284277 PROSPECTUS Enveric Biosciences, Inc. 1,229,330 Shares of Common Stock 1,666,666 Series A Warrants to Purchase up to 1,666,666 Shares of Common Stock 1,666,666 Series B Warrants to Purchase up to 1,666,666 Shares of Common Stock 437,336 Pre-Funded Warrants to Purchase 437,336 Shares of Common Stock 3,770,668 Shares of ...

03.02.2025

Enveric Biosciences Inc.

Notice of Effectiveness (Form EFFECT)

Notice of Effectiveness UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Notice of Effectiveness Effectiveness Date: January 30, 2025 5:15 P.M. Form: S-1 CIK: 0000890821 Company Name: Enveric Biosciences, Inc. File Number: 333-284277 Attachments Original document Permalink Disclaimer Enveric Biosciences Inc. published this content on January 30, 2025 , a ...

31.01.2025

Enveric Biosciences Inc.

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Press Releases Enveric Biosciences Announces Pricing of $5 Million Public Offering By wpengine January 30, 2025 No Comments CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depressi ...

31.01.2025

Enveric Biosciences Inc.

Amendment to Initial Registration Statement (Form S-1/A)

As filed with the Securities and Exchange Commission on January 30, 2025 Registration Statement No. 333-284277 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 95-4484725 (State ...

30.01.2025

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Press Releases Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office By wpengine January 30, 2025 No Comments Allowed claims protect composition of matter and methods of use for EB-003, a neuroplastogen targeting undertreated mental health indications CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ...

30.01.2025

Enveric Biosciences Inc.

Amendment to Initial Registration Statement (Form S-1/A)

As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. 333-284277 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 95-4484725 (State or other ...

30.01.2025

Enveric Biosciences Inc.

Amendment to Current Report (Form 8-K/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A ( Amendment No. 1 ) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or oth ...

27.01.2025

Enveric Biosciences Inc.

Proxy Results (Form 8-K)

Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (this "Current Report") is incorporated herein by reference. Attachments Original document Permalink Disclaimer Enveric Biosciences Inc. published this content on January 21, 2025 , a ...

21.01.2025

Enveric Biosciences Inc.

Initial Registration Statement (Form S-1)

As filed with the Securities and Exchange Commission on January 14, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 95-4484725 (State or other jurisdiction of (Primary ...

14.01.2025

Enveric Biosciences Inc.

Regulation FD Presentation Form 8 K

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Enveric Biosciences Inc. published this content on January 03, 2025 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 03, 2025 at 21:19:11.579 .

03.01.2025

Enveric Biosciences Inc.

Proxy Statement (Form DEF 14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted ...

18.12.2024

Enveric Biosciences Inc. - news published 259 - readings 4.281

Enveric Biosciences Inc.

Regulation FD Presentation (Form 8-K)

Enveric Biosciences Inc.

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Inc.

Enveric Biosciences Announces Pricing of $5 Million Public Offering (Form 8-K)

Enveric Biosciences Inc.

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences Inc.

Supplemental Prospectus (Form 424B4)

Enveric Biosciences Inc.

Notice of Effectiveness (Form EFFECT)

Enveric Biosciences Inc.

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Inc.

Amendment to Initial Registration Statement (Form S-1/A)

Enveric Biosciences Inc.

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences Inc.

Amendment to Initial Registration Statement (Form S-1/A)

Enveric Biosciences Inc.

Amendment to Current Report (Form 8-K/A)

Enveric Biosciences Inc.

Proxy Results (Form 8-K)

Enveric Biosciences Inc.

Initial Registration Statement (Form S-1)

Enveric Biosciences Inc.

Regulation FD Presentation Form 8 K

Enveric Biosciences Inc.

Proxy Statement (Form DEF 14A)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member